Methodological issues in longitudinal studies: Vestibular schwannoma growth rates in neurofibromatosis 2

Journal of Medical Genetics

Volumn 42, Issue 12, 2005, Pages 903-906

  Baser, M E ^a   Mautner, V F ^b   Parry, D M ^c   Evans, D G R ^d  

^a University Hospital Eppendorf ^*

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; DATA ANALYSIS; HUMAN; METHODOLOGY; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; UNITED KINGDOM;

EID: 29144503195     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2005.031302     Document Type: Review

References (15)

1. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-18.
2. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-61.
3. Mautner VF, Lindenau M, Baser ME, Hazim W, Tatagiba M, Haase W, Samii M, Wais R, Pulst SM. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-5.
4. Baser ME, Makariou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg 2002;96:217-22.
5. Mautner VT, Baser ME, Thakkar S, Feigen U, Friedman JM, Kluwe L. Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. J Neurosurg 2002;96:223-8.
6. Slattery WH III, Fisher LM, Iqbal Z, Oppenheimer M. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 2004;25:811-17.
7. Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996;106:694-9.
8. Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DG. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002;71:715-23.
9. Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, Ramsden RT, Evans DGR. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet 2004;75:231-9.
10. Rosenberg SI, Silverstein H, Gordon MA, Flanzer JM, Willcox TO, Silverstein J. A comparison of growth rates of acoustic neuromas: non-surgical patients vs. subtotal resection. Otolaryngol Head Neck Surg 1993;109:482-7.
11. Nutik SL, Babb MJ. Determinants of tumor size and growth in vestibular schwannomas. J Neurosurg 2001;94:922-6.
12. Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 1993;52:106-13.
13. Antinheimo J, Haapasalo H, Seppälä M, Sainio M, Carpén O, Jääskeläinen J. Proliferative potential of sporadic and neurofibromatosis 2-associated schwannomas as studied by MIB-1 (Ki-67) and PCNA labeling. J Neuropathol Exp Neurol 1995;54:776-82.
14. Laasonen EM, Troupp H. Volume growth rate of acoustic neurinomas. Neuroradiology 1986;28:228-33.
15. Ogawa K, Kanzaki J, Ogawa S, Yamamoto M, Ikeda S, Shiobara R. The growth rate of acoustic neuromas. Acta Otolaryngol Suppl 1991;487:157-63.